ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK. These include:
• The Development of a Novel Immunoassay for the Detection and Quantification of Murine Neutrophil Elastase (Ashleigh Kennedy)
• Sputum Storage Conditions and their Effect on the Quantification of Active Protease Biomarkers for COPD (Diane Ramsay)
• Evaluation of NEATstik® – A novel point of care test for the detection of active neutrophil elastase in sputum (Charlene Robb)
Dr David Ribeiro, CEO of ProAxsis, said: “We’re pleased to be able to share this new data with the COPD community, and look forward to continuing our ongoing collaborations with the University of Oxford, Belfast Hospital Trust and Chiesi Pharmaceuticals.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University Belfast.
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com
Related News
ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American …
ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes …
Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London …
